Dr. Paula Klein, MD
Claim this profileMount Sinai Beth Israel Comprehensive Cancer Center West
Area of expertise
Breast Cancer
Paula Klein, MD has run 6 trials for Breast Cancer. Some of their research focus areas include:
Breast Cancer
Paula Klein, MD has run 3 trials for Breast cancer. Some of their research focus areas include:
Affiliated Hospitals
Mount Sinai Beth Israel Comprehensive Cancer Center West
Icahn School Of Medicine At Mount Sinai
Clinical Trials Paula Klein, MD is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting
2 awards
Phase 3
40 criteria
DNA-Guided Adjuvant Therapy
for Breast Cancer
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Recruiting
1 award
Phase 2
9 criteria
More about Paula Klein, MD
Clinical Trial Related
2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Paula Klein, MD has experience with
- Paclitaxel
- Palbociclib
- Pertuzumab
- Trastuzumab
- Anastrozole
- Avelumab
Breakdown of trials Paula Klein, MD has run
Breast Cancer
Breast cancer
Breast Disorder
Breast Disease
HER2-Positive Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Paula Klein, MD specialize in?
Paula Klein, MD focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are ER positive.
Is Paula Klein, MD currently recruiting for clinical trials?
Yes, Paula Klein, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Paula Klein, MD has studied deeply?
Yes, Paula Klein, MD has studied treatments such as Paclitaxel, Palbociclib, Pertuzumab.
What is the best way to schedule an appointment with Paula Klein, MD?
Apply for one of the trials that Paula Klein, MD is conducting.
What is the office address of Paula Klein, MD?
The office of Paula Klein, MD is located at: Mount Sinai Beth Israel Comprehensive Cancer Center West, New York, New York 10011 United States. This is the address for their practice at the Mount Sinai Beth Israel Comprehensive Cancer Center West.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.